Clinical trial

Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC

NCT03402464

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Icotinib combined dihydroaremisinin Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2018-01-01

PhasePHASE2

Conditions

EGFR Positive Non-Small Cell Lung Cancer,Adenocarcinomaunresolved

Interventions

Icotinib combined dihydroaremisininDRUG

Sponsors & collaborators

Peking University Cancer Hospital & Institutelead sponsor

Betta Pharmaceuticals Co., Ltd.collaborator

Mapped research locations

BeijingChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03402464 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.